WuXi Biologics Advances European Biomanufacturing at CPHI Milan

WuXi Biologics participated in CPHI Milan 2026, emphasizing its role in supporting Europe's expanding biomanufacturing sector. At the event, which convened over 62,000 pharmaceutical professionals, the company focused on demonstrating how its technologies and global network advance the development and reliable supply of biologics.

The European biologics market is experiencing significant growth, driven by an aging population and the increasing prevalence of chronic diseases. With an estimated market value of $123.75 billion in 2025, projections through 2035 indicate a need for faster development, dependable manufacturing, and resilient regional supply chains. WuXi Biologics aims to meet this demand through its integrated CRDMO platform and strategically located European facilities.

The company highlighted the importance of quality assurance, noting that as of August 2026, WuXi Biologics had passed 49 regulatory inspections, including 23 by the FDA and EMA, alongside over 2,000 GMP quality audits by global clients. This track record demonstrates the company's capability to ensure consistent high quality and operational reliability from development through to supply.

WuXi Biologics' global manufacturing network, spanning Ireland, Germany, the United States, China, and Singapore, provides supply chain agility and resilience. Its operations in Dundalk, Ireland, and Wuppertal, Germany, are particularly crucial for strengthening its European presence. The Dundalk site has already established itself as a commercial manufacturing hub, bringing production closer to key European markets and regulatory environments.